The Digital Marketing Officer is an exciting new role that reflects the strategic importance of digital marketing to Cochrane ...

Sustained-release naltrexone may slightly increase illicit opioid use and serious adverse events compared to opioid agonists, with uncertain effects on retention and acceptability. It may reduce ...

Title: Head of Technology Specifications: 6 months – F ixed term contract – Full time Salary: £63,000 per annum (will be ...

Due to a lack of robust evidence, the effects of melatonin on quality of life and sleep quality in people receiving treatment for cancer are unclear. Melatonin might not increase the risk of adverse ...

Level III sleep studies may result in little to no difference in clinical outcomes when compared to Level 1 sleep studies in people with suspected OSA. Level IV sleep studies may not increase ...

Acupuncture may reduce pain assessed with different scales during the procedure, with little to no difference in any harms, when compared to no intervention. The evidence is very uncertain about the ...

The included studies assessed antibiotics, bovine colostrum, Shiga toxin binding agent (Synsorb Pk) and monoclonal antibodies (Urtoxazumab) against Shiga toxin for secondary prevention of HUS in ...

The evidence does not currently support a clear benefit or harm for routine intravenous thrombolysis amongst people receiving endovascular thrombectomy. Amongst participants receiving endovascular ...

Clinical staff should be vigilant when applying the currently available neonatal rating scales. Further development of rating scale content and testing for structural validity are necessary and should ...

El documentalista del Grupo Cochrane de Hipertensión (Cochrane Hypertension) buscó ensayos controlados aleatorizados en las siguientes bases de datos hasta abril de 2018 y de nuevo en marzo de 2020: ...